Conclusion: The group with AHG without DM had the poorest in-hospital mortality and long-term prognosis of all.
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Analysis for tight control of hyperglycemia with basal-bolus regimen in diabetic patients with acute coronary syndrome Introduction: Treatment of hyperglycemia in diabetic patients hospitalized for acute coronary syndrome (ACS) in coronary care units (CCU) is controversial, given that tight control could worsen ischemic symptoms, if hypoglycemia occurs. The aim of our study was to analyze the clinical outcomes of diabetic patients suffering from ACS, admitted in CCU, comparing those asigned to "tight control" of hyperglycemia (basal insulin regimen plus nutritional insulin and corrective complementary doses) versus those asigned to a "loose control " (rapid-acting insulin before meals, called "sliding-scale"). Methods: We analyzed 318 patients with diabetes admitted for a period of three years for ACS in our CCU. 206 were controlled with rapid-acting insulin before the meals (loose control), three doses daily, and 112 with basal-bolus regimen with fixed dose of ultra-slow insulin at night, and three preprandial ultrafast insulin bolus, corrected with additional doses depending on preprandial capilar glycemia (tight control). We analyzed the clinical characteristics of both groups, mean blood glucose reached, the incidence of hypoglycemia, cardiovascular events during hospitalization (reinfarction, stroke, and urgent revascularization), bleeding, the average stay in CCU and the mortality rate at 7 and 28 days. Results: Both groups had similar baseline clinical characteristics, with a mean age of 68 years, high prevalence of cardiovascular risk factors, mainly of ACS without ST elevation and Killip class I-II. The tight control group achieved significantly better glycemic control (156 mg/dl versus 254 mg/dl, p <0.05), no significant increase in hypoglycemia. The rate of stroke and major and minor bleeding was similar in both groups, but the tight control group showed a lower incidence of reinfarction and need for urgent revascularization (2.7% versus 11.7%, p <0.05), and lower mortality at 7 and 28 days (8.7% versus 21.7%, p <0.05). Also, the average stay was significantly shorter (4.7 days versus 9.8, p <0.05). Conclusions: In our series, tight control of hyperglycemia with basal-bolus regimen in diabetic patients admitted for ACS, improves glycemic control without increasing the incidence of hypoglycemia and reduces cardiovascular events and mortality.
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Relationship between preprocedual serum 1,5-anhydroglucitol concentrations and restenosis after implantation of drug-eluting stent Background: Restenosis after percutaneous coronary intervention (PCI) still remains as a clinically important problem in this drug-eluting stent (DES) era. Patients with diabetes mellitus are particularly prone to restenosis after PCI. Postprandial hyperglycemia has been shown to be related to the progression of atherosclerosis and to promote neointimal hyperplasia. While serum 1,5-anhydroglucitol (1,5-AG) has been used as an appropriate marker for postprandial hyperglycemia, the association between 1,5-AG and restenosis after DES implantation has not been clarified. Methods: Among 251 consecutive patients with stable effort angina who were electively implanted a single DES in our hospital, follow-up angiography was performed in 126 patients. 22 patients were excluded because of chronic renal failure which has been shown to influence serum 1,5-AG concentrations. Finally study subjects were composed of 104 patients. We analyzed their quantitative coronary angiography at the time of stent implantation and 9 months after the procedure. Furthermore, we also examined their glucose profiles including 1,5-AG and other conventional risk factors of coronary artery disease in fasting state before stent implantation. Results: In-stent restenosis (ISR) occurred in 13 patients (14.2%) out of 104 patients. Baseline patients' clinical characteristics and lesion characteristics were not different between patients with and without ISR. Moreover, the procedure devices including type of DES were similar in both groups. Serum 1,5-AG concentrations were significantly lower in patients with ISR compared to patients without ISR (12.99±7.8μg/dl vs. 18.7±9.0μg/dl, P=0.027), whereas levels of HbA1c and other glycemic parameters were not significantly different between 2 groups. The receiver operating characteristic analysis for serum 1,5-AG was performed to predict restenosis. The area under the curve of serum 1,5-AG was 0.68 for restenosis (cutoff value 15.68μg/ml, sensitivity 61.4%, specificity 68.8%). Conclusion: When DES was implanted under the similar lesions and conditions, patients with ISR showed significantly lower serum 1,5AG concentrations compared to patients without ISR. Serum 1,5-AG concentrations may be a useful indicator to predict restenosis after DES implantation. Purpose: The Diabetes Mellitus (DM) represents an additional metabolic handicap in cardiac Patients (pts). The aim of this study was to determine in a cohort of cardiac pts whether training-induced improvements in aerobic capacity and work performance are related and independent from the presence of DM Methods: From September 2007 to September 2012, three hundred twenty one male cardiac pts, referred for outpatient Cardiac Rehabilitation (CR), were divided in two groups: 144 (44.85%) pts with diabetes mellitus (DM), mean age 60.1±3.9 years (Group A), and 177 (55.15%) pts without DM (Group B), mean age 59.2±7 years. All pts performed a Cardiopulmonary Exercise Testing (CPET) before and 
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